Cosmetic Ingredient Review Report Status
This article was originally published in The Rose Sheet
Executive SummaryData compiled by "The Rose Sheet" from information in CIR reports and the Sept. 23 CIR meeting. Usage information is not all inclusive. Number of uses supplied by FDA on a voluntary industry basis
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.